Nuvation Bio Inc. (NASDAQ: NUVB) is a US-based pharmaceutical company focused on developing targeted oncology therapies for patients with genetically defined cancers. The company’s strategy centres on precision medicines designed to improve efficacy while reducing the toxicity associated with traditional chemotherapy. 

Nuvation’s first commercialised product is IBTROZI (taletrectinib), an oral, next-generation treatment for ROS1-positive non-small cell lung cancer. Taletrectinib is differentiated by its ability to overcome resistance to earlier therapies and penetrate the brain to treat metastatic disease. Beyond this asset, the company maintains a developing pipeline that includes safusidenib for glioma and early-stage targeted therapies for solid tumours, supporting longer-term growth optionality. 

Major developments include the FDA's approval of Taletrectinib on June 11, 2025, marking Nuvation Bio’s transition into a commercial-stage company. Commercialisation began immediately in the US, alongside established partnerships in China and Japan, enabling rapid international market access while limiting execution risk. Looking ahead, the company plans broader global expansion in 2026, in a venture with Eisai Co., Ltd., Canada, Australia, the EU and additional regions.

Finally, the company is managed by its founder, Dr David Hung, whose prior success includes funding and selling Medivation to Pfizer for $14bn. Given the recent FDA approval, early commercial and global expansion plan, and experienced leadership, we view NuvationBio as an attractive investment at an early commercial stage, with meaningful upside as revenue scales and the pipeline matures.